The treatment products R&D continue to lead, and product
sales are steadily advancing.
HANGZHOU, China, March 28, 2024 /PRNewswire/ -- On March 28, 2024, Broncus Medical
(02216.HK) (the "Company" or "we" ) announced annual results
for FY 2023.
In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to
the previous year. Of which, total revenue from Mainland China was
US$8.62 million with a significant
increase of 48%.
(i) In terms of clinical and product R&D:
We have completed the follow-up visit to the pivotal clinical
trial of Zhiheng RF-II in 2023. The product is the world's first
transbronchial interventional treatment product for lung cancer.
The results of the clinical trial showed safety and efficacy
of RF-II in the treatment of lung cancer in clinical use. And the
study data is also used for the license applications for NMPA
medical devices.
For the TLD Radiofrequency Ablation System, an innovative device
for the treatment of acute exacerbation of COPD, we completed the
enrollment of over 40 patients at more than 20 trial sites in the
pre-marketing clinical trials in 2023.
(ii) In terms of market access:
In 2023, the domestic version of InterVapor®,
domestic version of Lungpoint and BroncTru™, a disposable
transbronchoscopic puncture dilatation catheter, obtained NMPA
registration certificates.
For global market, InterVapor® was successively
approved in Thailand, Chinese Taiwan, Malaysia and Indonesia during the period.
(iii) In terms of commercialization:
In Mainland China, InterVapor® for COPD has been
commercialized in more than 20 hospitals. About 100 hospitals have
been exposed to the technology with local medical insurance
coverage gradually being implemented.
For our navigation products, according to public information,
the market share in Mainland China reached 40% in 2023.
For consumable products, such as BroncTru™, the disposable
transbronchoscopic puncture dilatation catheter, has been applied
in multi-scenarios in diagnosis and treatment of lung diseases.
In the future, we will continue to make efforts to product
pricing, cost control and commercialisation to realise a positive
growth in product sales.
View original
content:https://www.prnewswire.com/news-releases/broncus-medical-02216hk-announces-annual-results-for-2023-302102689.html
SOURCE Broncus Holding Corporation